Q3 2024 Earnings Forecast for Deciphera Pharmaceuticals, Inc ... - MarketBeat
| CMPX Stock | USD 1.63 0.07 4.49% |
Slightly above 55% of Compass Therapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Compass Therapeutics stock suggests that some investors are interested at this time. Compass Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Compass Therapeutics' earnings reports, geopolitical events, and overall market trends.
Compass |
Q3 2024 Earnings Forecast for Deciphera Pharmaceuticals, Inc ... MarketBeat
Read at news.google.com
 |
Compass Therapeutics Fundamental Analysis
We analyze Compass Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Compass Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Compass Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Compass Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Compass Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Compass Therapeutics stock to make a market-neutral strategy. Peer analysis of Compass Therapeutics could also be used in its relative valuation, which is a method of valuing Compass Therapeutics by comparing valuation metrics with similar companies.
Peers
Compass Therapeutics Related Equities
| GLUE | Monte Rosa | 13.72 | ||||
| LYRA | Lyra Therapeutics | 10.53 | ||||
| VIGL | Vigil Neuroscience | 7.39 | ||||
| MGTX | MeiraGTx Holdings | 3.36 | ||||
| CGEM | Cullinan Oncology | 2.75 | ||||
| IDYA | Ideaya Biosciences | 1.37 | ||||
| MLTX | MoonLake Immunotherapeuti | 0.35 | ||||
| REPL | Replimune | 0.21 | ||||
| AVTE | Aerovate Therapeutics | 0.38 | ||||
| ANAB | AnaptysBio | 0.64 | ||||
| PEPG | PepGen | 0.98 | ||||
| KRON | Kronos Bio | 1.04 | ||||
| IVA | Inventiva | 1.12 | ||||
| KROS | Keros Therapeutics | 1.38 | ||||
| GOSS | Gossamer Bio | 1.41 | ||||
| GPCR | Structure Therapeutics | 1.78 | ||||
| TYRA | Tyra Biosciences | 2.00 | ||||
| ELVN | Enliven Therapeutics | 4.05 | ||||
| NVCT | Nuvectis Pharma | 4.55 | ||||
| NAMS | NewAmsterdam Pharma | 4.57 | ||||
| PRTC | PureTech Health | 5.04 |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.